Stay updated on Amgen Press Releases

Sign up to get notified when there's something new on the Amgen Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Amgen Press Releases page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    Amgen has made significant updates, including the FDA approval of IMDELLTRA™ for extensive-stage small cell lung cancer and the launch of OTEZLA® for pediatric plaque psoriasis, while several upcoming presentations and financial results have been removed from the site.
    Difference
    100%
    Check dated 2024-09-18T16:26:13.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Amgen has presented new data for its first-in-class treatment, Imdelltra™ (Tarlatamab-DLLE), for small cell lung cancer at WCLC 2024.
    Difference
    29%
    Check dated 2024-09-11T07:06:39.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Amgen has announced several significant updates, including the availability of Otezla® for pediatric plaque psoriasis, upcoming presentations at major healthcare conferences, and the approval of Blincyto® for a specific type of leukemia.
    Difference
    100%
    Check dated 2024-09-04T03:47:36.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Amgen has made several significant announcements, including the approval of Blincyto® for B-ALL and the first quarter 2024 financial results, while notable deletions include the second quarter 2024 financial results and the announcement of the third quarter dividend.
    Difference
    100%
    Check dated 2024-08-20T23:48:43.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Amgen has reported its second quarter 2024 financial results and announced a third quarter dividend, along with a webcast for the financial results.
    Difference
    38%
    Check dated 2024-08-06T21:35:40.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    In June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive Phase 3 trial results for Uplizna® and plans to present at several major healthcare conferences.
    Difference
    100%
    Check dated 2024-07-30T21:34:49.000Z thumbnail image

Stay in the know with updates to Amgen Press Releases

Enter your email address, and we'll notify you when there's something new on the Amgen Press Releases page.